Table 1.

General clinical characteristics of the study population stratified by tertiles of serum osteoprotegerin

Characteristic, Mean (±SD) or n (%)Tertile 1 (1.21 to 5.03 pmol/L), n = 117Tertile 2 (5.05 to 7.45 pmol/L), n = 117Tertile 3 (7.46 to 22.31 pmol/L), n = 117Pa
Demographics
    age (years)56.4 (±11.6)60.2 (±9.3)63.6 (±9.1)<0.01
    female gender29 (24.8)31 (26.5)47 (40.2)0.02
    black race56 (47.9)70 (59.8)73 (62.4)0.06
Comorbid conditions
    diabetes44 (37.6)66 (56.4)73 (62.4)<0.01
    cardiovascular disease26 (22.2)44 (37.6)53 (45.3)<0.01
    hypertension99 (84.6)99 (84.6)110 (94.0)0.04
    current/former smoker52 (44.4)65 (55.6)69 (59.0)0.07
Examination
    body mass index (kg/m2)31.7 (±7.0)31.9 (±7.2)30.9 (±6.2)0.54
    waist circumference (cm)107.5 (±17.1)107.8 (±17.3)105.2 (±16.9)0.44
    systolic BP (mmHg)124 (±21)131 (±21)136 (±21)<0.01
    diastolic BP (mmHg)75 (±15)76 (±14)73 (±14)0.43
    aortic pulse wave velocity (m/s)b,c8.0 (7.0, 9.8)9.4 (7.9, 11.9)10.6 (9.0, 12.2)<0.01
Laboratory
    albuminuria
        <30 mg/day50 (52.1)40 (41.7)45 (45.0)
        30 to 299 mg/day24 (25.0)31 (32.3)27 (27.0)0.62
        ≥300 mg/day22 (22.9)25 (26.0)28 (28.0)
    eGFR (ml/min per 1.73 m2)51.5 (±13.9)48.3 (±13.6)42.8 (±13.5)<0.01
    serum albumin (g/dl)4.0 (±0.37)3.9 (±0.40)3.8 (±0.36)<0.01
    hs-CRP (mg/L)b2.2 (1.0, 6.1)2.5 (0.9, 5.5)2.4 (1.0, 6.8)0.63
Medications
    ACE inhibitors61 (52.6)57 (49.6)51 (44.0)0.41
    lipid-lowering medications62 (53.5)76 (66.1)73 (62.9)0.12
  • eGFR, estimated GFR; hs-CRP, high-sensitivity C-reactive protein; ACE, angiotensin-converting enzyme.

  • a P value using ANOVA (continuous variables) or Pearson's chi-squared test (categorical variables).

  • b Values presented as median (interquartile range). P-values calculated from log-transformed variable.

  • c Among n = 226 with concurrent pulse wave velocity available.